iCrowdNewswire
Spain Brazil Russia France Germany China Korea Japan

Artificial Intelligence driven Marketing Communications

Jul 17, 2019 7:36 AM ET

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need.


Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need.

iCrowd Newswire - Jul 17, 2019

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantias strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.

Contact Information:

Hugo Harrod








Tags:    Equity Crowdfunding, Wire, United Kingdom, English